Breakthrough cancer pain: Epidemiology, characteristics and management

CNS Drugs

Volumn 13, Issue 5, 2000, Pages 313-319

  Fine, Perry G ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; FENTANYL CITRATE; OPIATE DERIVATIVE;

CANCER PAIN; CHRONIC PAIN; DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; NOMENCLATURE; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 0034053944     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013050-00002     Document Type: Review

References (55)

1. 1. Bonica JJ. Cancer pain. In: Bonica JJ, editor. The management of pain. 2nd ed. Vol. I. Philadelphia (PA): Lee and Febiger, 1990: 400-14
2. 2. Bonica JJ. Treatment of cancer pain: current status and future needs. Adv Pain Res Ther 1985; 9: 589-616
3. 3. World Health Organization. Cancer Pain Relief. Geneva: World Health Organization, 1986
4. 4. Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO methods for cancer pain relief. Cancer 1987; 59: 850-6
5. 5. Jacox A, Carr DB, Payne R, et al. Management of cancer pain. In: Clinical practice guideline no. 9 (AHCPR publication no. 94-0592). Rockville (MD): Agency for Health Care Policy and Research, 1994
6. 6. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 4th ed. Glenview (IL): American Pain Society, 1999
7. 7. Storey P. Primer of palliative care [note: The Academy of Hospice Physicians is now the American Academy of Hospice and Palliative Medicine with offices in Reston (VA)]. Gainesville (FL): Academy of Hospice Physicians, 1994
8. 8. Fine PG. The hospice companion: processes to optimize care during the last phase of life. Scottsdale (AZ): VistaCare, Inc., 1998
9. 9. Wrede-Seaman L. Symptom management algorithms: a handbook for palliative care. 2nd ed. Yakima (WA): Intellicard, 1999
10. 10. Portenoy RK, Hagen NA. Breakthrough pain: definition and management. Oncology 1989; 3 Suppl.: 25-9
11. 11. Swanson G, Smith J, Bulich R, et al. Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: a report of 117 patients. J Clin Onc 1989; 7 (12): 1903-8
12. 12. Wagner JC, Souders GD, Coffman LK, et al. Management of chronic cancer pain using a computerized ambulatory patient-controlled analgesia pump. Hosp Pharm 1989; 24: 639-44
13. 13. Portenoy RK, Maldonado M, Fitzmartin R, et al. Oral controlled-release morphine sulfate: analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients. Cancer 1989; 63 (11): 2284-8
14. 14. Ashburn MA, Fine PG, Stanley TH. Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: a case report. Anesthesiology 1989; 71 (4): 615-7
15. 15. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273-81
16. 16. Mercadante S. What is the definition of breakthrough pain [letter]? Pain 1991; 45: 107-8
17. 17. Payne R. Transdermal fentantyl: suggested recommendations for clinical use. J Pain Symptom Manage 1992; 7 Suppl. 3: 40-4
18. 18. McQuay HJ, Jadad AR. Incident pain. Cancer Surv 1994; 21: 17-24
19. 19. Hammack JE, Loprinzi CL. Use of orally administered opioids for cancer-related pain. Mayo Clin Proc 1994; 69: 384-90
20. 20. Payne R. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin Oncol 1998; 25 Suppl. 3: 47-53
21. 21. Cleary JF, Coluzzi PH, Fine PG, et al. Cancer pain management: update on breakthrough pain. Semin Oncol 1997; 24 (5) suppl. 16: 1-42
22. 22. McCaffery M, McKitrick LF. Planning for breakthrough pain. Am J Nurs 1996; 96 (6): 24
23. 23. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998; 24: 425-32
24. 24. Coluzzi PH. Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care 1998; 15: 13-22
25. 25. Patt RB, Ellison NM. Breakthrough pain in cancer patients: characteristics, prevalence, and treatment. Oncology 1998; 12: 1035-46
26. 26. Evans N, Palmer A. Controlling breakthrough pain in palliative care. Nursing Standard 1998; 13 (7): 53-4
27. 27. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. The management of chronic pain in patients with breast cancer. Can Med Assoc J 1998; 158 Suppl. 3: 71-81
28. 28. Scholz M. An effective way to manage breakthrough pain. RN 1999 May; 62 (5): 102
29. 29. Levy MH. Pain control in patients with cancer. Oncology 1999; 13 Suppl. 5: 9-14
30. 30. Moulin DE, Kreeft JH, Murray-Parsons, et al. Comparison of continuous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991; 337: 465-8
31. 31. Deschamps M, Band PR, Hislop TG, et al. The evaluation of analgesic effects in cancer patients exemplified by a double-blind, crossover study of immediate-release versus controlled release morphine. J Pain Symptom Manage 1992; 7 (7): 384-92
32. 32. Walsh TD, MacDonald N, Bruera E, et al. A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. Am J Clin Oncol 1992; 15: 268-72
33. 33. Arkinstall W, Sandler A, Goughnour B. Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial. Pain 1995; 62: 169-78
34. 34. Wong JO, Chiu GL, Tsao CJ, et al. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997; 35 (1): 25-32
35. 35. Hagen N, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997; 79: 1428-37
36. 36. Rosenbluth RJ, Reder RF, Slagle NS, et al. Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. Cancer Invest 1998; 16: 562-71
37. 37. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81: 129-34
38. 38. Petzke F, Radbruch L, Zech D, et al. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage 1999; 17: 391-401
39. 39. Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998; 16 (3): 179-83
40. 40. Lichtblau L, Belgrade M, Auld R, et al. Pharmacologic management of cancer pain in rural Minnesota. J Pain Symptom Manage 1996; 12 (5): 283-9
41. 41. Weber M, Huber C. Documentation of severe pain, opioid doses and opioid-related side effects in outpatients with cancer: a retrospective study. J Pain Symptom Manage 1999; 17 (1): 49-54
42. 42. Sloan PA, Donnelly MB, Schwartz, et al. Cancer pain assessment and management by housestaff. Pain 1996; 67: 475-81
43. 43. Paice J, Fine PG. Pain at end of life. In: Ferrell BR, Coyle N, editors. The Oxford textbook of palliative nursing care. New York (NY): Oxford University Press. In press
44. 44. Robison JM, Wilkie DJ, Campbell B. Sublingual and oral morphine administration. Nurs Clin North Am 1995; 30: 725-43
45. 45. Coluzzi PH. Sublingual morphine: efficacy reviewed. J Pain Symptom Manage 1998; 16: 184-92
46. 46. Fine PG, Streisand J. A review of oral transmucosal fentanyl citrate: potent, rapid and noninvasive opioid analgesia. J Palliat Medicine 1998; 1: 55-64
47. 47. Fine PG, Marcus M, De Boer J, et al. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991; 45: 149-53
48. 48. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75: 223-9
49. 49. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for the treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998; 90 (8): 611-6
50. 50. Christie J, Simmonds M, Patt R. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998; 16 (10): 3238-45
51. 51. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79: 303-12
52. 52. Patt RB. Long-term safety and efficacy of oral transmucosal fentanyl citrate (OTFC, Actiq™) for treatment of breakthrough cancer pain [abstract]. 16th Annual Scientific Meeting, American Pain Society: 1997 Oct 23-26; New Orleans
53. 53. Rhiner M, Coluzzi PH. Managing breakthrough pain. New method expands treatment options. Adv Nurse Pract 1998; 6: 41-3
54. 54. Pasero C, McCaffery M. Managing breakthrough pain with OTFC. Am J Nurs 1999; 99 (4): 20
55. 55. Fine PG. Clinical experience with Actiq™ (oral transmucosal fentanyl citrate) for the treatment of cancer pain. Today's Therapeutic Trends 1999; 17: 1-11